Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) had its price objective lowered by HC Wainwright from $14.00 to $11.00 ...

Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report)‘s stock had its “buy” rating restated by D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have ...

CUPERTINO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage ...

Fintel reports that on January 10, 2025, Maxim Group upgraded their outlook for Reviva Pharmaceuticals Holdings ...

Trading Recap. On Friday, Reviva Pharmaceuticals Holdings Inc (RVPH) stock saw a modest uptick, ending the day at $1.88 which repr ...

In recent trading, Reviva Pharmaceuticals Holdings Inc (RVPH) stock price has shown some volatility, fluctuating -19.80% over the last ...

Maxim upgraded Reviva Pharmaceuticals (RVPH) to Buy from Hold with a $7 price target The company has taken steps to address its financing ...

H.C. Wainwright lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $11 from $14 and keeps a Buy rating on the shares. Johnson ...

Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst The FDA's approval of Bristol Myers Squibb's Cobenfy for schizophrenia opens ...

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory ...